These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9011420)

  • 1. [Splenectomy in osteomyelofibrosis. Indications and outcome].
    Böhner H; Rötzscher VM; Tirier C; Heit W; Greiner J
    Chirurg; 1996 Oct; 67(10):1016-9. PubMed ID: 9011420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis.
    Montague N; De La Ossa M
    Blood; 2010 Oct; 116(14):2410. PubMed ID: 20949696
    [No Abstract]   [Full Text] [Related]  

  • 3. Idiopathic myelofibrosis without dacryocytes.
    Chen GL; Liu E; Naidoo K; Popat U; Coetzer TL; Prchal JT
    Haematologica; 2006 Jun; 91(6 Suppl):ECR29. PubMed ID: 16785132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
    Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
    Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases.
    Lafaye F; Rain JD; Clot P; Najean Y
    Nouv Rev Fr Hematol (1978); 1994 Oct; 36(5):359-62. PubMed ID: 7892130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative splenectomy in myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A
    Leuk Lymphoma; 2001; 42(5):901-11. PubMed ID: 11697645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
    Ward HP; Block MH
    Medicine (Baltimore); 1971 Sep; 50(5):357-420. PubMed ID: 4940717
    [No Abstract]   [Full Text] [Related]  

  • 8. Myelofibrosis and rapid thrombocytolysis. A case report.
    Kutti J; Bergström AL; Ridell B
    Acta Med Scand; 1977; 201(3):249-55. PubMed ID: 848365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia.
    Mohite U; Pathare A; al Kindi S; Hiwase D; Vadakkepat N; Knox-Macaulay H
    Haematologia (Budap); 2002; 32(4):495-9. PubMed ID: 12803124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for splenectomy in the anemic forms of myelofibrosis with myeloid metaplasia of the spleen].
    Dechavanne M; Viala JJ; Barbier Y; Revol L
    Sem Hop; 1972 Apr; 48(17):1187-92. PubMed ID: 4342370
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pylethrombosis following splenectomy (author's transl)].
    Aufschnaiter M; Salzer GM
    MMW Munch Med Wochenschr; 1981 Oct; 123(40):1503-5. PubMed ID: 6795460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly.
    Kawano N; Saito N; Yoshida S; Kitanaka A; Shide K; Marutsuka K; Ohshima K; Shimoda K
    Tohoku J Exp Med; 2022 Feb; 256(2):119-125. PubMed ID: 35173090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia.
    Petroianu A
    Int Surg; 1996; 81(2):177-9. PubMed ID: 8912088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenectomy for agnogenic myeloid metaplasia.
    Gomes MR; Silverstein MN; Remine WH
    Surg Gynecol Obstet; 1967 Jul; 125(1):106-8. PubMed ID: 6026679
    [No Abstract]   [Full Text] [Related]  

  • 15. Splenectomy? No, thank you!
    Huić D; Labar B; Huić M; Radman I; Dodig D; Mrsić M
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1677. PubMed ID: 15241628
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of splenectomy in the treatment of myelofibrosis].
    Melikian AL; Kolosova LIu; Sokolova MA; Kovrigina AM; Silaev MA; Giliazitdinova EA; Gemdzhian ÉG; Karagiulian SR
    Ter Arkh; 2013; 85(8):69-76. PubMed ID: 24137967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
    Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
    Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
    DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
    Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
    Barosi G; Ambrosetti A; Buratti A; Finelli C; Liberato NL; Quaglini S; Ricetti MM; Visani G; Tura S; Ascari E
    Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for and results of splenectomy in different hematological disorders.
    Böhner H; Tirier C; Rötzscher VM; Heit W
    Langenbecks Arch Chir; 1997; 382(2):79-82. PubMed ID: 9128872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.